吡非尼酮对特发性肺纤维化患者咳嗽的影响
本研究旨在客观测量吡非尼酮对特发性肺纤维化(IPF)伴明显咳嗽患者咳嗽的影响,并评估其对主观咳嗽及生活质量指标的作用。研究指出IPF咳嗽常对镇咳治疗无反应,而吡非尼酮可能减少咳嗽。
要点
- 吡非尼酮可减少IPF患者24小时客观咳嗽计数。
- 吡非尼酮改善IPF患者主观咳嗽测量指标。
- IPF咳嗽常对镇咳治疗无反应,吡非尼酮可能有效。
核心结论
- 在IPF患者中,吡非尼酮减少客观24小时咳嗽计数并改善主观咳嗽测量。
研究设计与样本
- 研究旨在客观测量吡非尼酮对IPF伴明显咳嗽患者咳嗽的影响,并评估主观咳嗽及生活质量指标。
主要发现
- 吡非尼酮减少IPF患者客观24小时咳嗽计数。
- 吡非尼酮改善IPF患者主观咳嗽测量指标。
临床怎么用
- 对于IPF伴明显咳嗽的患者,可考虑使用吡非尼酮以减轻咳嗽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with IPF, pirfenidone reduces objective 24-h cough counts and improves subjective measures of cough http://ow.ly/iiGu30f7Pea Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease. In patients with IPF, cough is one of the most disabling symptoms and is an independent predictor of disease progression [1–3]. Cough in IPF is often non-responsive to antitussive therapy [4], and studies on cough are scarce and have unfortunately not yet resulted in effective treatments. Several observations suggest that pirfenidone, an anti-fibrotic drug, might decrease cough [5, 6]. We aimed to measure objectively the effect of pirfenidone on cough in patients with IPF and substantial cough. In addition, we assessed the effect of pirfenidone on subjective cough and quality of life (QoL) measures.
引用
- van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017. PMID: 29051272. doi:10.1183/13993003.01157-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。